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Abstract
Background: Approximately 30–50% of patients with major depressive disorder can be classed as treatment resistant,
widely defined as a failure to respond to two or more adequate trials of antidepressants in the current episode.
Treatment resistant depression is associated with a poorer prognosis and higher mortality rates. One treatment option
is to augment an existing antidepressant with a second agent. Lithium and the atypical antipsychotic quetiapine are
two such add-on therapies and are currently recommended as first line options for treatment resistant depression.
However, whilst neither treatment has been established as superior to the other in short-term studies, they have yet to
be compared head-to-head in longer term studies, or with a superiority design in this patient group.
Methods: The Lithium versus Quetiapine in Depression (LQD) study is a parallel group, multi-centre, pragmatic, open-
label, patient randomised clinical trial designed to address this gap in knowledge. The study will compare the clinical and
cost effectiveness of the decision to prescribe lithium or quetiapine add-on therapy to antidepressant medication for
patients with treatment resistant depression. Patients will be randomised 1:1 and followed up over 12 months, with the
hypothesis being that quetiapine will be superior to lithium. The primary outcomes will be: (1) time to all-cause treatment
discontinuation over one year, and (2) self-rated depression symptoms rated weekly for one year via the Quick Inventory
of Depressive Symptomatology. Other outcomes will include between group differences in response and remission rates,
quality of life, social functioning, cost-effectiveness and the frequency of serious adverse events and side effects.
Discussion: The trial aims to help shape the treatment pathway for patients with treatment resistant depression, by
determining whether the decision to prescribe quetiapine is superior to lithium. Strengths of the study include its
pragmatic superiority design, broad inclusion criteria (external validity) and longer follow up than previous studies.
Trial registration: ISRCTN registry: ISRCTN16387615, registered 28 February 2016. ClinicalTrials.gov: NCT03004521,
registered 17 November 2016.
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Background
Major depressive disorder (MDD) is a highly prevalent
and disabling illness requiring effective treatment in
order to reduce symptom severity and improve quality
of life [1, 2]. Current clinical guidelines recommend the
use of antidepressant medication in cases of moderate to
severe MDD [3]. However, approximately 30–50% of pa-
tients fail to adequately respond to both first and second
line antidepressant treatment trials, and can therefore be
described as treatment resistant [3–5]. Existing evidence
clearly indicates that the prognoses for patients with
treatment resistant MDD (TRD) can be improved with
adequate multimodal and/or successive treatment trials
[4, 6]. Given that TRD is associated with a generally
poorer prognosis, higher mortality rates and higher
healthcare utilisation costs than MDD alone [7, 8], the
importance of ensuring that the most effective available
medication is fully utilised in clinical practice is clear.
Treatment options for patients with TRD include increas-
ing the dose of a patient’s existing antidepressant, switching
to another antidepressant (same or different class), or
augmenting the existing antidepressant medication with a
second agent, for example an additional antidepressant,
mood stabiliser, or antipsychotic medication [3]. Increases
in dosage have been associated with increased efficacy for
some antidepressants [7, 9–11] but not for others [12–15].
Switching to an alternative antidepressant is generally
suggested in cases where a patient has either made no
response, or is not tolerating their current medication [3],
but remission rates to third or fourth line antidepressant
treatments are in the order of just 10–15% [4]. For TRD
patients in whom there has been a partial response to
current antidepressant treatment, augmentation is usually
recommended [3]. However, beyond these general princi-
ples, there remains much uncertainty about when to switch
and when to augment treatments.
One augmentation strategy is to prescribe a combination
of antidepressant medications. However, recent evidence
from a large randomised controlled trial indicated that this
approach is no more effective than antidepressant mono-
therapy, questioning its appropriateness [16]. The use of
lithium or atypical second-generation antipsychotic aug-
mentation is an approach supported by several recent
meta-analyses [17, 18]. This is reflected in the National In-
stitute of Clinical Excellence (NICE) and the British Associ-
ation for Psychopharmacology (BAP) treatment guidelines,
which emphasise that add-on treatments are a standard
treatment pathway for TRD, and include lithium and newer
atypical antipsychotics, such as quetiapine, aripiprazole,
olanzapine and risperidone, as first line options [3, 19].
Despite these recommendations, few studies have com-
pared the efficacy of lithium versus atypical antipsychotic
augmentation head-to-head [3, 20, 21]. The largest and argu-
ably best study to date compared lithium and quetiapine
extended release (XR) over just 6 weeks, and found quetia-
pine to be non-inferior to lithium add-on therapy in patients
with TRD [20]. Lithium versus quetiapine augmentation has
also been compared in a pilot study of 20 patients, which
reported significant reduction in depressive symptoms in
both groups, but a greater decrease in Hamilton Depression
Rating Scale (HDRS) scores from day 14 onwards in the que-
tiapine group [21]. However, neither of these comparisons
have included a long term follow up, which is needed to
ensure that the most effective treatment option is fully
utilised in clinical practice, particularly given the chronic
nature of TRD, the associated high rates of relapse [8], and
the fluctuating nature of depressive symptoms (even in those
responding to acute phase treatment) [16]. Clinical guide-
lines also advise that responders should continue taking the
effective medication for at least 6–12 months [3, 19].
Therefore a clinical trial comparing lithium and quetiapine
augmentation, with frequent assessment of symptoms and
12 month follow up is clearly warranted.
In the present study, lithium augmentation will com-
prise one treatment arm, as it is the first-choice add-on
treatment for patients with TRD according to the World
Federation of Societies of Biological Psychiatry Task Force
[22], and a first line treatment option recommended by
NICE and BAP [3, 19]. Quetiapine was selected as the
atypical antipsychotic comparator, as there is strong
evidence for the efficacy of quetiapine augmentation
versus placebo [23–25], and it is currently licenced for
marketing as an add-on treatment for TRD in the UK in
its XR formulation [19]. Although NICE does support the
use of other atypical antipsychotics (aripiprazole, risperi-
done and olanzapine) as add-on treatments in TRD, and
there is some evidential support for their use [17, 26],
quetiapine is the only atypical antipsychotic to have been
previously studied under trial conditions in a head-to-
head comparison with lithium, meaning at least compar-
able short-term effectiveness between the two treatments
under trial conditions is known [20]. While this study by
Bauer and colleagues reported quetiapine to be non-
inferior to lithium over a six week treatment course, there
was also some indication that quetiapine may be more
clinically effective than lithium. This included lower
depression severity scores (Montgomery-Åsberg Depres-
sion Rating Scale, MÅDRS), reported as early as day 4 of
treatment, and less sleep disturbance [20]. Additionally, a
network meta-analysis comparing augmentation agents in
TRD found lithium and quetiapine to both be more
effective than a placebo, but indicated that the efficacy of
quetiapine was more robust than lithium [27].
Objectives and hypothesis
This study aims to determine whether the decision to
prescribe quetiapine is more clinically and cost effective
than the decision to prescribe lithium over a longer term
Marwood et al. BMC Psychiatry  (2017) 17:231 Page 2 of 12
in a randomised clinical trial powered to detect superior-
ity. We propose a 12 month follow up period, hypothe-
sising that quetiapine will be superior to lithium in
terms of our primary outcomes: time to all-cause treat-
ment discontinuation and average depressive symptom
burden over 12 months.
We hope to help shape a modified treatment pathway
for TRD in which one augmenter is preferential to the
other. However, if quetiapine is not found to be clinically
superior based on our primary and secondary outcomes,
the results of the cost effectiveness analysis, or individual
level predictive factors, may determine the most appro-
priate choice for each patient.
The trial will recruit patients with TRD: defined as the
failure to adequately respond to two or more therapeutic
trials of antidepressant treatments in the current episode
(at adequate dose and duration) [3, 8]. This definition of
treatment resistance is in line with the point at which
treatment augmentation is recommended in clinical
practice [3] and at which the evidence suggests clinical
equipoise between the two treatments [20].
This protocol paper is consistent with SPIRIT (Stand-
ard Protocol Items: Recommendations for Interventional
Trials) 2013 recommendations [28] (checklist attached).
Methods/design
Study design
LQD is a phase 4, 12-month, parallel group, multi-centre,
patient 1:1 randomised, pragmatic, open-label, superiority
trial, comparing the clinical and cost-effectiveness of the de-
cision to prescribe lithium versus quetiapine as add-on treat-
ment to antidepressant medication in patients with TRD.
Participants
We will recruit participants who fulfil the following
inclusion criteria:
1. Under the care of a GP and/or adult mental health
services
2. Current episode of depression meeting Diagnostic and
Statistical Manual of Mental Health Disorders – Fifth
Edition (DSM-5) [29] criteria for MDD (single or
recurrent episode) assessed using the Mini
International Neuropsychiatric Interview, Version 7
(MINI 7.0) [30]
3. HDRS - 17 item [31] score ≥ 14 at screening
4. Any gender and aged 18 years or over
5. TRD [3, 32]: defined as failing to adequately respond
to at least two antidepressant therapies, prescribed
for at least 6 weeks at minimum therapeutic dose, as
determined by the Maudsley Prescribing Guidelines
(MPG) and/or British National Formulary (BNF)
[33, 34]
6. Current antidepressant treatment has remained
unchanged for ≥6 weeks
7. Provision of written, informed consent
Exclusion criteria for participants are:
1. Diagnosis of bipolar disorder (defined as meeting
DSM-5 criteria for bipolar 1 or 2) on the MINI 7.0
2. Diagnosis of current psychosis
3. Use of lithium or quetiapine during current
depressive episode
4. Ongoing use of another atypical antipsychotic
5. Known contraindication to use of either lithium or
quetiapine
6. Currently participating in another clinical trial of an
investigational medical product
7. Insufficient degree of comprehension or attention to
be able to engage in trial procedures
8. Pregnancy, actively trying for pregnancy, or
breastfeeding
Recruitment procedure and assessments
Participant recruitment will take place across three of the
UK National Institute of Health Research (NIHR) Clinical
Research Network hubs: South London, the North East and
North Cumbria, and Thames Valley and South Midlands.
Recruitment is underway at four sites within these hubs:
the South London and Maudsley National Health Service
(NHS) Foundation Trust (SLaM); Northumberland, Tyne
and Wear NHS Foundation Trust (NTW); Oxford Health
NHS Foundation Trust (OHT); and Tees, Esk and Wear
Valleys NHS Foundation Trust (TEWV).
Potential participants will be identified primarily at
routine secondary care clinic appointments or via Consent
for Contact initiatives within the trusts (e.g. http://
www.slam.nhs.uk/research/patient-involvement/current-op-
portunities/consent-for-contact) alongside advertisements,
and via Participant Identification Centres including primary
care and external UK NHS trusts to enhance recruitment.
Randomisation and blinding
The study will randomise individual participants 1:1 to the
decision to prescribe lithium or quetiapine, stratified by
recruiting region (London, Oxfordshire, or North East
England), depression severity (HDRS-17), and TRD severity
(failure of two / three or more antidepressant treatments in
the current episode), using block randomisation with ran-
domly varying block size. Randomisation will be conducted
by a trial researcher using an independent online service
provided by UK Clinical Research Collaboration registered
King’s Clinical Trial Unit, with unique patient identification
numbers generated by the InferMed MACRO system.
This is an unblinded study, whereby treating clinicians,
trial researchers, and patients will be aware of the treatment
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allocation for patients where applicable to their role. In
order to reduce the potential for assessor bias, the following
clinician-rated assessments will be completed at follow up
visits by an assessor who is blind to the patient’s medication
(face-to-face or via phone): 1) MÅDRS [35], and 2) Clinical
Global Impressions scale (CGI) [36]. Trained trial re-
searchers and clinicians may perform blinded assessments,
but must not have access to the trial database for the rele-
vant site to reduce the likelihood of unblinding (access to
the trial database is granted on a site by site basis,
dependent on role). The blinded assessor will remind the
participant not to reveal treatment allocation at the start of
the assessment and will confirm they remained blinded to
treatment allocation throughout the assessment.
Primary outcomes
a) Difference in time to all-cause treatment discontinu-
ation over 12 months post-randomisation between
lithium and quetiapine using survival analysis methods,
with time being between the first prescription and
discontinuation of the medication to which the patient
was randomised.
b) Longitudinal Depression Severity: the difference in the
area under the curve between lithium and quetiapine
over 12 months post-randomisation in the self-rated
Quick-Inventory of Depressive Symptomatology
(QIDS-SR) [37], assessed weekly via the True Colours
system (www.truecolours.nhs.uk), using a linear mixed
model, covarying for baseline QIDS-SR score.
Secondary outcomes
The secondary outcomes will be measured at 8 and
52 weeks, and differences between lithium and quetiapine
assessed at both time points. Continuous secondary out-
comes measured over time will use appropriate generalised
linear models, covarying by baseline score where applicable.
Where there are repeated measures of a continuous vari-
able, the analysis will be set in the mixed model framework.
Time to event variables will be analysed using survival
methods. The secondary outcomes are as follows:
 Clinician-rated depression severity (continuous total
score on the MÅDRS).
 Clinician-rated response and remission rates
(defined as proportion with ≥50% reduction in
baseline MÅDRS total score and MÅDRS total
score ≤ 10, respectively).
 Global improvement (proportion of patients with a
CGI-improvement score of ‘much’ or ‘very much
improved’).
 Health-related quality of life (summary index
EuroQol-5D, EQ-5D score [38]).
 Social functioning (continuous total Work & Social
Adjustment Scale (WSAS) score [39]).
 Self-report adherence to treatment (5-item
Medication Adherence Report (MARS-5)
continuous total scores and exploratory cut-offs
categorising patients as either adherent or non-
adherent [40]).
 Physical health parameters: weight (kg) and blood
pressure (mmHg).
 Time to commencement of trial medication from
randomisation (and number of patients commencing
therapy in each arm).
 Time to uptake of a new intervention for depression
from randomisation (pharmacological or non-
pharmacological) over 12 months (and proportion of
patients in each arm receiving new interventions).
 Side Effects (continuous total score on the Patient
Rated Inventory of Side Effects (PRISE) [41]).
 Frequency of Serious Adverse Events (SAEs).
Secondary outcomes, except for SAEs, will be adjusted
for multiple comparisons. SAEs will be tabulated as
number of SAEs in each group, and number of people
reporting an SAE in each group over 12 months. We will
also summarise the reasons for clinicians not prescribing
and patients not commencing the medication they are
randomised to, reasons for treatment discontinuation, the
number of withdrawals, and the reasons for withdrawals
from the trial. However, we will not test the difference
between the groups on these variables statistically.
Additional outcomes
For a full list of tertiary and ancillary trial outcomes
please visit clinicaltrials.gov. Two key ancillary outcomes
are detailed below:
 Cost-effectiveness: This data will be gathered from
the Client Service Receipt Inventory (CSRI) [42],
modified for TRD, asked at baseline, 8, 26, and 52 week
study visits. Cost-effectiveness analyses will be
conducted from a health and social care, and a societal
perspective. This will include trial and concomitant
medication costs, healthcare costs (including hospital,
community-based, social and primary care services),
costs to statutory and non-statutory services, impact
on caregivers and families, and days off work due to
health problems.
 Predictors of treatment response: for example,
baseline staging of treatment resistance (Maudsley
Staging Method, MSM [32]), depression
characteristics (e.g. severity (HDRS [31]), chronicity,
family history, recurrence (MINI 7.0), psychiatric
comorbidity (MINI 7.0), subtype (e.g. typical versus
atypical, clinician rated Inventory of Depressive
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Symptomatology (IDS-C) [43]), personality
(Standard Assessment of Personality [44]), type of
antidepressant (e.g. selective serotonin reuptake
inhibitor (SSRI) vs. non-SSRI), hypomanic symptoms
(16-item hypomanic checklist (HCL-16) [45] at
baseline) and sociodemographic factors (e.g. sex, age,
ethnicity, body mass index). Briefly, the analysis
would build a predictive model of response using an
appropriate variable selection procedure (i.e. manual
forward stepwise regression).
Interventions
As this is a pragmatic study, trial medications will be pre-
scribed open-label and no measures will be taken to inter-
vene with patients’ medication adherence. Trial clinicians
will be advised to keep patients’ existing antidepressant
treatment(s) at a stable dose within the therapeutic range,
as defined in the MPG and BNF [33, 34]. The following
recommendations for titration and dosing of each of the
two treatment arms will be provided, in line with current
best practice guidelines [33, 34]. However failure to adhere
to these guidelines will not constitute a protocol deviation:
Lithium arm: lithium carbonate/citrate, added on to the
current antidepressant. The dose should be adjusted to
achieve a serum-lithium concentration of 0.4–1.0 mmol/l
12 h after a dose. Serum level checks should be performed
on days 4–7 of treatment and be repeated every week until
dosage has remained constant for 4 weeks aiming for an
optimal therapeutic plasma level of 0.6–1.0 mmol/l [22, 33].
Quetiapine arm: quetiapine fumarate (XR or immediate
release formulation) added on to the current
antidepressant, taken once daily before bedtime.
Recommended dose titration: 50 mg on days 1 and 2
and 150 mg on day 3, aiming for a dose of 300 mg/day
by week 2, if tolerated. Thereafter, flexible dosing will
follow in the range 150–300 mg/day according to
tolerance (as per Bauer et al. 2013) [23]. In elderly
patients (>65 years old), the dose titration protocol
should be: 50 mg/day on days 1–3, increasing to
100 mg/day on day 4, 150 mg/day on day 8 and
300 mg/day not before day 22 of treatment, if required.
Dosing regimens may need to be altered in the case of
concomitant administration of drugs that interact with
either quetiapine or lithium.
The initial prescription of a study medication and any
essential pre-prescription safety checks must be overseen
by a trial clinician. This is followed by a fully flexible con-
tinuation phase for up to 52 weeks post-randomisation, in
which treatment is shared between primary and secondary
care as appropriate according to standard NHS practice in
the relevant trust.
In this trial, patients will be randomised to the decision
to prescribe either lithium or quetiapine. This means that
in each case, the treating trial clinician will decide whether
or not to prescribe the medication that the patient has
been randomised to, according to their clinical judgement.
It is therefore possible that a small proportion of rando-
mised patients will not receive the medication that they
are allocated to. This may be due to a previously unknown
contraindication to the study medication arising during
the pre-prescribing safety checks (exclusion criteria for
trial entry is known contraindications to lithium or quetia-
pine only). The required safety checks are: electrocardio-
gram, if clinically indicated (both treatment arms) and
pre-lithium blood tests (renal function, thyroid function,
full blood count, serum calcium). These tests must be
conducted prior to prescription, unless they have been
completed within a sufficiently recent period according to
the prescribing clinician’s judgement.
All patients will be followed up for 12 months, regard-
less of medication status. It is expected that a significant
proportion of patients will fail to respond or tolerate the
medication and will terminate treatment before 12 months.
Treatment may also be extended beyond the follow up
period at the discretion of the patient’s clinician. All
concomitant pharmacological and non-pharmacological
interventions are permitted throughout the duration of
the trial and will be recorded by the trial team.
Assessments
All assessments, data entry and randomisation will be
conducted by trained trial researchers with oversight from
the clinical chief (AJC) and principal investigators (AHY,
RHMW, JG, RN). See Table 1 for details of all study mea-
sures and Fig. 1 for a flow chart of trial procedures.
Screening visit
All participants must provide written informed consent at
the start of the screening assessment. Consent may be taken
by a trial clinician, or delegated non-clinical researcher with
trust approval. Confirmation of eligibility will be signed off
by a trial clinician at the end of this assessment.
Baseline, weekly monitoring and follow up visits
If the baseline assessment is more than 7 days after the
screening visit, the screening assessments (excluding demo-
graphic information) will be repeated to ensure that the
participant still meets the required eligibility criteria. Ran-
domisation will be conducted at Week/Time Point 0, which
is the day of the baseline visit. Follow-up assessments with
trial researchers will be conducted at 8 (+ − 1) weeks, 26
(+ − 2) weeks, and 52 (+ − 2) weeks post-randomisation.
Patients will also be asked to complete three question-
naires weekly via the True Colours system (https://trueco-
lours.nhs.uk): the QIDS-SR, WSAS, and study specific
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questions about medication status. True Colours is an on-
line monitoring tool on which questionnaires can be com-
pleted via email, text, or by logging on to the website. For
patients without internet access, a paper version can be
provided. Automated reminders will be sent to participants
on a day and time of their choosing.
Optional study blood tests will be conducted at baseline,
8 and 52 week visits (agreement to clinical blood tests
throughout the trial duration is not optional). Optional
blood tests include samples for genetic and cytokine ana-
lysis, along with hair samples to assess cortisol levels, and
saliva samples for genetic analysis where blood samples
are not provided. This will be done in collaboration with
the Biomedical Research Council (BRC) BioResource.
Further optional measures include a qualitative interview
exploring patient experience of True Colours as a mood
monitoring tool (conducted at one follow up appoint-
ment) and the THINC-it tool for cognitive function [46].
Table 1 Summary of measures
Time point Screening Baseline
(Week 0)
Follow up
Weekly
Assessments
Weeks 0–52
Week 8
(+ − 1 weeks)
Week 26
(+ − 2 weeks)
Week 52
(+ − 2 weeks)
Written informed consent √
Assessment of eligibility √
MINI 7.0 to confirm MDD and other comorbid axis 1 disorders √
Assessment of depression severity (HDRS-17) √
Assessment of medication history in current depressive episode √
Sociodemographic / Psychiatric and Medical History
(including MSM)
√
Assessment of concomitant medication and
non-pharmacological therapies
√ √ √ √ √
Clinician-rated assessment of clinical symptoms (MÅDRS, CGI) √ √ √ √
Randomisation √
Clinician-rated depression severity (including subtype: IDS-C)b √ √
Hypomanic checklist (HCL-16)b √
Assessment of side effects (FIBSERb and PRISE) √ √ √
Assessment of quality of life (EQ-5D) √ √ √ √
Assessment of cognition (THINC-ita, b and DSCTb) √ √ √ √
Weekly True Colours self-rated measures: QID-SR, WSAS, and trial
medication status
√ √ √ √ √
Self-Rated clinical measures (ASRMb, Maudsley VAS measuresb,
GAD-7b, SAPASb)
√ √ √ √
Assessment of costs (CSRIb and employment statusb) √ √ √ √
Treatment satisfaction (TSQMb) √ √ √
Adherence (baseline to antidepressantb, follow up
to trial medication)
√ √ √ √
Qualitative assessment of patient experience of True Coloursa, b √ or √ or √
Physical health (weight, height, blood pressure,
pulse rate, waist circumference)
√ √ √ √
Blood tests (FBC, U&Es, LFTs, TFT, glucose, lipids, calcium)a, b √ √ √
Lithium and quetiapine serum levelsa, b √ √
BioResource genetic/cortisol/cytokine sample collectiona, b √ √ √
MINI 7.0 Mini International Neuropsychiatric Interview, Version 7.0, MDD major depressive disorder, HDRS Hamilton Depression Rating Scale – 17 items, MSM
Maudsley Staging Method, MÅDRS Montgomery-Åsberg Depression Rating Scale, CGI Clinical Global Impressions, IDS-C Inventory of Depressive Symptomatology –
Clinician Rated, HCL-16 Hypomanic Checklist – 16 items, FIBSER Frequency, Intensity and Burden of Side Effects Ratings, PRISE Patient Rated Inventory of Side
Effects, EQ-5D EuroQol-5D health index, THINC-it THINC-it tool for cognitive dysfunction in Major Depressive Disorder, DSCT Digit Symbol Coding Test, WSAS Work
and Social Adjustment Scale, ASRM Altman Self-Rating Mania Scale, VAS Visual Analogue Scale, GAD-7 Generalised Anxiety Disorder questionnaire – 7 items, SAPAS
Standard Assessment of Personality: abbreviated Scale, CSRI Client Service Receipt Inventory, FBC Full blood count, U&Es Urea, electrolytes and creatinine, LFTS
Liver function tests, TFT Thyroid function tests
a Optional and/or collected in a subset of participants
b Measures solely for tertiary and ancillary analyses
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One section of the CSRI collects data about the patient’s
principal formal or informal carer. Where applicable, the
carer can complete this questionnaire following their
provision of written informed consent. Where this is not
possible, responses from the patient will be accepted.
At 4 weeks post-randomisation, participants will receive
a phone call from a trial researcher to determine the date
they began taking their allocated medication. If applicable,
the reason the patient has not commenced their medica-
tion will be recorded and this question will be repeated at
follow-up visits to determine if a patient has subsequently
begun the allocated medication.
All study data will be stored on a custom-designed,
online data entry system which is compliant with Good
Clinical Practice guidelines, and created and maintained
by King’s Clinical Trials Unit (InferMed MACRO version
4.0). The system is programmed to perform validation
checks for data quality purposes (e.g. range checks to
avoid data entry errors) and flags out of range or missing
data for monitoring purposes. It also has a built in audit
trail to aid data monitoring.
Statistical methods for analysing primary and secondary
outcomes
A full statistical analysis plan will be drawn up prior to
completion of data collection. The main analysis will follow
an intention to treat (ITT) principle, whereby patient data
are analysed by treatment group, regardless of the medica-
tion status of patients throughout the follow-up period.
Participant flow will be presented in a CONSORT
diagram. For analysis of the listed primary and secondary
outcomes, missing baseline data will be filled in using im-
putation [47]. Models will covary for randomisation stratifi-
cation factors throughout. For the self-report QIDS-SR
score a linear mixed model, covarying by baseline score,
will be used for the estimation of the mean treatment
difference and 95% confidence interval (CI) over the course
of the trial. Full information maximum likelihood methods
will be used for analysis, which will account for missing
data under the missing at random assumption. Error
distributions will be checked using Q-Q plots. Time to
discontinuation will be calculated from first prescription
date to treatment discontinuation, and will be analysed
Fig. 1 Flow Chart of Trial Procedures
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using Kaplan-Meier methods and Cox regression models,
providing the hazard ratio for treatment discontinuation in
lithium versus quetiapine, and associated 95% CI.
Continuous secondary outcomes measured over time will
use generalised linear models appropriate to the variable
distribution covarying by baseline where applicable, and using
mixed models where there are repeated measurements. Ad-
justment for multiple testing will be presented [48].
For measures where missingness is above 5% and where
the absence of repeated measurement gives less confi-
dence in the adequacy of the missing data properties of
maximum likelihood, we may undertake a sensitivity ana-
lysis within a multiple imputation framework [49].
Power calculation
Based on our power calculation and superiority design,
we require 276 patients to be randomised. When consid-
ering the sample size required, we have considered both
the primary outcome measures of time to all cause treat-
ment discontinuation and longitudinal symptom severity
as assessed by QIDS-SR scores. This sample size was
calculated based on the following assumptions:
 Treatment discontinuation: estimated 20%
discontinuation from treatments by 8 week follow
up visit (as per Bauer et al., 2013) [20]), and 50%
treatment discontinuation for lithium and 30% for
quetiapine by 52 weeks.
 Missing data: 40% missingness for each of the post-
randomisation QIDS-SR scores was allowed for.While
the missingness has been assumed independent over
time, the QIDS-SR scores are assumed uniformly
correlated with a correlation of 0.6 [47]. We have
allowed the discontinuation status at follow-up to be
unknown for 10% of the sample.
 Effect size: The minimum clinically significant
difference for outcomes in depression treatment is
widely taken to be 3 points on the HDRS [3, 50].
This corresponds to an effect size of 0.38 between
treatments. We wish to see a difference of this effect
size in the QIDS-SR score sustained over the
duration of the trial and so will estimate the
effect as an area under the curve.
 Power: All power calculations are for two-tailed tests
and alpha = 0.05.
With a sample size of 276 at baseline and 10% loss to fol-
low up, we expect 248.4 patients to complete the trial. The
Stata stpower command gave 90% power using a logrank
test to detect a difference in the time to discontinuation
with 50% (lithium) and 70% (quetiapine) as the proportions
of participants remaining on assigned treatment. This
determined the lower limit of the sample size. Applying this
sample size to the self-report QIDS-SR data we also needed
to account for the likely haphazard nature of missing data
points at each assessment time point. We used simulation
and the non-central chi-square method. Using 1000
samples, a simple random intercept model covarying for
baseline, a time dummy variable and with a single average
combined treatment effect, this number of participants will
provide 99.7% power to detect an effect size of 0.38 (with 1
degree of freedom, χ2 = 3.84, and non-centrality
parameter = 20.86).
Monitoring
There is no planned interim analysis and no specific
“stopping rules” for the study. We have an independent
Data Monitoring and Ethics Committee and an inde-
pendent Trial Steering Committee. SAEs will be re-
ported to the relevant bodies for all patients throughout
their involvement in the trial. Clinicians have the right
to discontinue the study drug in the event of identified
contraindications, inter-current illness, pregnancy,
adverse drug reactions, adverse events, protocol viola-
tions, administrative causes, or for other reasons. We
will adhere to NHS confidentiality practice, and to the
Research Governance Framework in monitoring, audit-
ing and managing the research.
Discussion
This protocol paper describes a pragmatic randomised
clinical trial designed to determine whether the decision
to prescribe quetiapine is more clinically and cost effective
than lithium for patients with TRD over 12 months. The
chronicity of TRD, in which patients often fluctuate
between states of remission and relapse [51], highlights
not only the importance of this research question, but also
the implementation of a 12 month follow up period. As
discussed, there have been no direct head-to-head com-
parisons of these treatments with a follow up period of
greater than six weeks. This is insufficient given that up to
80% of patients with TRD relapse within 12 months of
responding to treatment [8, 20]. Our choice of primary
outcome, a longitudinal measure of depression severity
(QIDS-SR), measured weekly over 12 months via the True
Colours system (www.truecolours.nhs.uk), recognises the
highly fluctuating nature of this disorder. True Colours
has been used to assess mood in prior research studies
with success [52] and facilitates the monitoring of all
cause treatment discontinuation across the full duration
of the trial.
The benefits of determining whether one of these
recommended and widely prescribed medications is
more effective for patients with TRD are clear. However
the results of this study should also positively impact
secondary care mental health teams and the wider NHS
by helping to minimise relapse rates and in doing so
alleviate some of the financial and time burden placed
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on mental health services. If there is no significant dif-
ference between lithium and quetiapine in the primary
outcomes of clinical effectiveness, the cost-effectiveness
analysis, which takes into account the different monitor-
ing requirements for these medications, may benefit
health bodies by informing them of the most cost-
effective of these two treatment options. In addition, our
further analyses may contribute to the growing body of
research examining predictors of treatment response in
depression, and the development of personalised mental
health care.
The potential impact of this trial is maximised by its
pragmatic design, which ensures that the results will be
directly applicable to real-world clinical practice. The
PRECIS-2 tool [51] was used to assess how far we have
achieved this and what elements of the design are most
pragmatic. A key pragmatic strength is our choice of pri-
mary outcomes (the effectiveness and tolerability of the
treatments) which are directly applicable to, and can
clearly be understood by, the patient group. Additionally,
our broad inclusion criteria and minimal exclusion cri-
teria enable us to capture as much variation in the TRD
population as possible and include the majority of pa-
tients that are likely to receive such an augmentation
therapy in routine clinical practice. Examples of this are
the inclusion of patients demonstrating suicidal ideation,
as this group is often excluded from clinical trials, and
the decision not to include an upper age limit (com-
monly set at 65 years for TRD clinical research) improv-
ing the applicability of our results to older patients [3].
Furthermore, alongside the recruitment of patients
from secondary care settings, where lithium or atyp-
ical antipsychotic augmentation is commonly initiated,
we are also recruiting patients from primary care. In
doing so we are ensuring that our samples reflect the
range of patients that should be considered for these
two augmentation therapies according to best practice
guidelines.
The pragmatic design of the trial is also reflected in our
decision to not dictate a specific dosing or monitoring
schedule. As discussed, clinicians are provided with best-
practice dosing and monitoring guidelines, but are free to
prescribe, monitor and discontinue the trial medication as
they find clinically appropriate.
The PRECIS-2 tool also highlighted some necessary
limitations to the trial’s pragmatism; primarily the large
number of measures conducted during the follow up
period. As with all pragmatically designed trials, there
must be a balance between the need for adequate data
collection and the additional burden this places on par-
ticipants, beyond what would be experienced in normal
clinical practice. However, all chosen measures were
deemed necessary by the study team to ensure that the
results of the trial aid the development of a modified
and evidence based treatment pathway for TRD, and
contribute to the improvement of treatment outcomes
in this patient group. Conducting a thorough psychiatric
history assessment to determine TRD staging and
depression characteristics, assessing personality traits re-
lating to refractoriness, evaluating mixed and atypical
depressive symptomatology, and collecting biological
samples to examine genetic and inflammatory markers
and changes in physical health, will allow for a thorough
comparison between the two treatments. In order to
minimise patient dropout, some of the measures associ-
ated with tertiary or ancillary outcomes only have been
made optional for participants. Additionally, information
will be gathered from medical records or at future follow
up visits where possible should a patient fail to attend or
complete an assessment.
The LQD study is a large scale trial designed to build on
evidence reported by previous short term comparisons of
lithium and quetiapine augmentation in patients with TRD
[21, 22]. In doing so, we hope to definitively determine
which of these two augmentation treatments (if either)
should be preferential over the other, improving patient
outcomes and minimising the burden that TRD places on
clinical resources.
Trial status
Recruitment is currently ongoing at 4 sites (SLaM, NTW,
OHT, and TEWV) and is set to continue until February
2019. It is anticipated that the trial will end in June 2020.
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